Table 2B.
Prostate Cancer Clinical Trials Consortium Studies*
| Drug/Agent | Clinical State12 | Number of Centers |
Mechanism | First in Human |
First in Prostate |
IRB Approval |
First Patient Enrolled |
Closed to Accrual |
|---|---|---|---|---|---|---|---|---|
| Cilengitide | Rising PSA castrate | 3 | As above | No | Yes | 10/7/2004 | 10/7/2004 | 2/1/2008 |
| Enzastaurin | Rising PSA castrate | 2 | PKC-β inhibitor | No | Yes | 3/28/2007 | 5/7/2007 | NA |
| GM-CSF and Docetaxel | Castrate metastatic | 2 | Cytotoxic/growth factor | No | No | 10/3/2006 | 4/1/2007 | NA |
| Cixutumumab | Rising PSA castrate | 3 | Anti–IGF-IR receptor antibody | No | Yes | 7/11/2007 | 8/11/2007 | NA |
| Ixabepilone | Castrate metastatic | 4 | Anti-androgen | No | No | 3/2/2006 | 4/11/2006 | NA |
| Ketoconazole, Hydrocortisone, Dutasteride | Rising PSA non-castrate | 4 | Hormonal | Yes | Yes | 5/30/2006 | 6/30/2006 | NA |
| Panobinostat | Castrate metastatic | 4 | Histone deacetylase inhibitor | No | Yes | 3/28/2006 | 4/26/2006 | 10/23/2007 |
| MDV3100 | Castrate metastatic | 3 | Anti-androgen | Yes | Yes | 6/29/2007 | 7/13/2007 | |
| Ipilimumab | Castrate metastatic | 3 | Anti-CTLA4 inhibitor | No | Yes | 8/11/2005 | 1/10/2006 | NA |
| MK-4721 | Castrate metastatic | 2 | Anti-PSCA antibody | Yes | Yes | 8/21/2007 | 10/3/2007 | NA |
| Oligonucleotide | Castrate metastatic | 2 | Antisense HSP-27 oligonucleotide | Yes | Yes | 6/6/2007 | 6/24/2007 | NA |
| Paclitaxel Poliglumex and Transdermal Estradiol | Castrate metastatic | 2 | Chemohormonal | No | Yes | 11/2/2006 | 2/28/2007 | NA |
| Plitidepsin | Rising PSA castrate | 2 | Depsipeptide | No | Yes | 3/3/2006 | 3/3/2006 | NA |
| Rapamycin | Localized disease | 3 | Immunosuppressant | No | No | 10/26/2005 | 8/15/2006 | NA |
| Sunitinib Malate | Castrate metastatic | 4 | Multitargeted receptor kinase inhibitor | No | Yes | 8/3/2005 | 10/10/2005 | NA |
| Suberoylanilide Hydroxamic Acid (SAHA) | Castrate metastatic | 4 | Histone deacetylase inhibitor | No | Yes | 3/2/2006 | 11/11/2006 | NA |
| Vorinostat | Localized disease | 2 | Histone deacetylase inhibitor | No | No | 11/29/2007 | 3/3/2008 | NA |
| Sagopilone (ZK-Epo) | Castrate metastatic | 3 | Cytotoxic | No | Yes | 10/6/2006 | 1/17/2006 | NA |
*
Table reflects active trials during the first 21 months of operation.
Abbreviations: GM-CSF = granulocyte-macrophage colony-stimulating factor; IGF-IR = type 1 insulin-like growth factor receptor; IRB = Institutional Review Board; mTOR = mammalian target of rapamycin; NA = not applicable; PKC = protein kinase C; PSA = prostate-specific antigen; PSCA = postrate stem cell antigen